Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of Cd8 T cells and enables sMIC tumors respond to PD1/PD-L1 blockade therapy

被引：0
|
作者：
Dhar, Payal [1 ]
Zhang, Jinyu [2 ]
Larrocha, Pablo Saenz-lopez [1 ]
Zhang, Bin [1 ]
Wainwright, Derek A. [1 ]
Wu, Jennifer D. [1 ]
机构：
[1] Northwestern Univ, Feinberg Sch Med, Evanston, IL 60208 USA
[2] East Tennessee State Univ, Johnson City, TN USA
来源：
JOURNAL OF IMMUNOLOGY | 2020年 / 204卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
165.12
引用
收藏
页数：2
相关论文
共 9 条
  • [1] Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC+ tumors respond to PD1/PD-L1 blockade therapy
    Zhang, Jinyu
    Larrocha, Pablo Saenz-Lopez
    Zhang, Bin
    Wainwright, Derek
    Dhar, Payal
    Wu, Jennifer D.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 (01):
  • [2] Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual costimulation of CD8 T cells and enables sMIC plus tumors to respond to PD1/PD-L1 blockade therapy.
    Zhang, Jinyu
    Larrocha, Pablo
    Dhar, Payal
    Wu, Jennifer
    CANCER IMMUNOLOGY RESEARCH, 2020, 8 (03) : 70 - 70
  • [3] Antibody targeting soluble NKG2D ligand sMIC sensitizes metastatic prostate tumor and other MIC+ tumors to PD1/PD-L1 blockade therapy in pre-clinical models
    Wu, Jennifer D.
    Zhang, Jinyu
    Larrocha, Pablo
    Dhar, Payal
    CANCER RESEARCH, 2019, 79 (13)
  • [4] Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy
    Fahmin Basher
    Payal Dhar
    Xin Wang
    Derek A. Wainwright
    Bin Zhang
    Jeffrey Sosman
    Zhe Ji
    Jennifer D. Wu
    Journal of Hematology & Oncology, 13
  • [5] Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy
    Basher, Fahmin
    Dhar, Payal
    Wang, Xin
    Wainwright, Derek A.
    Zhang, Bin
    Sosman, Jeffrey
    Ji, Zhe
    Wu, Jennifer D.
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)
  • [6] NKG2D CO-STIMULATION VIA ANTI-SMIC/MIC TARGETING ANTIBODY ENHANCES CD8 T CELL FUNCTIONAL HETEROGENEITY AND MEMORY DEVELOPMENT IN MOUSE PROSTATE TUMORS
    Smith, Tyler
    Liu, Sizhe
    Zhu, Lisha
    Wu, Jennifer
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1189 - A1189
  • [7] PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+ T cells
    Karwacz, Katarzyna
    Bricogne, Christopher
    MacDonald, Douglas
    Arce, Frederick
    Bennett, Clare L.
    Collins, Mary
    Escors, David
    EMBO MOLECULAR MEDICINE, 2011, 3 (10) : 581 - 592
  • [8] Interference with PD-L1/PD-1 co-stimulation results in effective anti-tumour immunity by preventing ligand-induced T cell receptor down-modulation in effector CD8 T cells
    Escors, D.
    Liechtenstein, T.
    Perez-Janices, N.
    Lanna, A.
    Bricogne, C.
    Karwaca, K.
    Guerrero-Setas, D.
    Breckpot, K.
    HUMAN GENE THERAPY, 2013, 24 (12) : A170 - A170
  • [9] Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment
    Spranger, Stefani
    Koblish, Holly K.
    Horton, Brendan
    Scherle, Peggy A.
    Newton, Robert
    Gajewski, Thomas F.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2014, 2
1